<DOC>
	<DOCNO>NCT01988857</DOCNO>
	<brief_summary>This study evaluate safety reactogenicity GSK Biologicals ' combined reduced-antigen-content diphtheria-tetanus-acellular pertussis ( dTpa ) vaccine , Boostrix™ give single injection 6-10 year old child . Data available globally age group four six year age use bridge age gap study aid registration vaccine child age four year .</brief_summary>
	<brief_title>Safety Booster Dose GlaxoSmithKline ( GSK ) Biologicals ' Boostrix™ Vaccine Healthy Vietnamese Children</brief_title>
	<detailed_description>A phase III , single-group , open-label study GSK Biologicals ' vaccine BoostrixTM administer booster vaccine dose healthy Vietnamese child age 6-10 year . A single booster dose BoostrixTM administer Visit 1 ( Day 0 ) subject observe Visit 2 ( Day 30 ) . Safety assess term solicited adverse event ( 4 day post vaccination ) , unsolicited adverse event ( 31 day post vaccination ) serious adverse event ( trial period ) . This protocol summary update follow administrative change add EudraCT number study .</detailed_description>
	<mesh_term>Diphtheria</mesh_term>
	<criteria>Subjects investigator believe parent ( ) /Legally Acceptable Representative ( ) [ LAR ( ) ] comply requirement protocol . A male female , include , 6 10 year age time vaccination . Written inform consent obtain parent ( ) /LAR ( ) subject . Written inform assent obtain subject addition inform consent sign parent ( ) /LAR ( ) , require local regulation . Healthy subject establish medical history clinical examination enter study . Subjects previously complete routine vaccination diphtheria , tetanus pertussis diseases accord local recommended vaccination schedule time receive vaccine last two year prior study dose administration . Female subject nonchildbearing potential may enrol study . Female subject childbearing potential may enrol study , subject : practiced abstinence adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire treatment period 2 month completion vaccination series . Child care . Use investigational nonregistered product study vaccine within 30 day precede booster dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug within six month prior vaccination . Inhaled topical steroid allow . Administration vaccine foreseen study protocol within 30 day prior booster vaccine dose , plan administration study period . Administration immunoglobulins and/or blood product within three month precede Visit 1 plan administration study period . Occurrence transient thrombocytopenia neurological complication follow early immunisation diphtheria and/or tetanus . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product . A history previous intercurrent diphtheria , tetanus pertussis disease . History reaction hypersensitivity likely exacerbate component vaccine . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . Major congenital defect serious chronic illness . Acute disease and/or fever time enrollment . Pregnant lactate female .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Vietnam</keyword>
	<keyword>Children</keyword>
	<keyword>Reactogenicity</keyword>
	<keyword>BoostrixTM</keyword>
	<keyword>Safety</keyword>
	<keyword>dTpa</keyword>
	<keyword>Booster</keyword>
	<keyword>Healthy</keyword>
</DOC>